- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Harbour BioMed Reports Strong 2025 Profit Outlook
Biopharmaceutical company expects profit to nearly double year-over-year.
Published on Feb. 4, 2026
Got story updates? Submit your updates here. ›
Harbour BioMed, a global biopharmaceutical company, announced a positive profit alert for the year ended December 31, 2025. The company expects total profit to range between $88 million and $95 million, compared to $2.7 million in 2024. The anticipated increase is attributed to continued growth of recurring revenue streams, accelerated expansion of global partnerships, and rapid business growth of its Nona Biosciences division.
Why it matters
Harbour BioMed's strong financial performance highlights the success of its unique business model, which focuses on leveraging its proprietary antibody technology platforms to drive innovation and secure lucrative collaborations with industry leaders. This positions the company for sustained growth and the ability to further invest in R&D to develop novel antibody therapeutics.
The details
Harbour BioMed's expected profit increase is primarily driven by three factors: 1) Continued growth of recurring revenue streams, such as the platform-based research collaborations with AstraZeneca and Bristol Myers Squibb; 2) Accelerated expansion of its global partner network, with revenue from out-licensing and collaboration of innovative products transforming into recurring revenue; and 3) Rapid business growth of its Nona Biosciences division, including revenue from technology licensing, platform-based services, and milestone payments.
- Harbour BioMed's fiscal year ended on December 31, 2025.
- The company announced the positive profit alert on February 3, 2026.
The players
Harbour BioMed
A global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology.
Dr. Jingsong Wang
Founder, Chairman and CEO of Harbour BioMed.
AstraZeneca
A global biopharmaceutical company with which Harbour BioMed has a platform-based research collaboration.
Bristol Myers Squibb
A global biopharmaceutical company with which Harbour BioMed has a platform-based research collaboration.
Nona Biosciences
A division of Harbour BioMed that has experienced rapid business growth.
What they’re saying
“This anticipated profit marks a key milestone for Harbour BioMed, validating the value of our unique business model. The strength of our proprietary technology platforms is being recognized through a growing number of deep, strategic collaboration with global leaders. Most importantly, these partnerships are not one-time events; they are evolving into a sustainable financial foundation that fuels our mission to discover and develop novel antibody therapeutics for patients worldwide.”
— Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed (Harbour BioMed Press Release)
The takeaway
Harbour BioMed's strong financial performance demonstrates the success of its innovative business model, which leverages proprietary technology platforms to drive strategic collaborations and fuel the development of novel antibody therapeutics. This positions the company for continued growth and the ability to further invest in R&D to address unmet medical needs.
